Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : T/FIF, a New Plateau -- Ignore unavailable to you. Want to Upgrade?

To: tuck who wrote (1952)	4/9/2003 10:21:55 AM
From: scaram(o)uche	Read Replies (1) \| Respond to of 2243

In general..... from the veteran biotech investor's perspective..... one looks past AACR to ASCO. I've never traded AACR. In the old days, virtually every abstract submitted to AACR was published. There was no peer review. Presentations are, and always have been, a different issue. But.... it's sort of like ASM versus ICAAC...... one meeting moves stocks, the other doesn't. But, in the day of "popcorn" and roving bands of traders who are looking to find suckers to take the potential downside of their momentary trades? You're correct to watch closely. If you have really primo data, you'll generally aim for ASCO.